4/A: CERO Therapeutics Holdings CEO Brian Atwood Amends Ownership Disclosure to Include Stock Options

Brian Atwood, CEO of CERO Therapeutics Holdings, files an amended Form 4 to include previously omitted stock options in his beneficial ownership disclosure following the company's recent business combination.

Summary

• Brian G. Atwood, CEO of CERO Therapeutics Holdings, filed an amended Form 4 with the SEC on March 11, 2024, to correct an omission in the initial filing made on February 16, 2024.
• The amendment updates Table II to include stock options held by Atwood.
• The reported transactions occurred on February 14, 2024, in connection with the Issuer's business combination.
• Atwood acquired 100,527 shares of Common Stock and 148,208 shares of Common Stock through the Atwood-Edminster Trust.
• The Atwood-Edminster Trust also acquired 1,002 shares of Series A Convertible Preferred Stock and 13,857 stock options.
• The earnout shares vest upon meeting certain conditions related to the volume weighted average price (VWAP) of the Common Stock or upon a change of control or the Issuer's submission of an IND application to the FDA.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily involves correcting a filing error and disclosing standard transactions related to a business combination. There are no explicit positive or negative implications for the company's performance.

Positives

• The reporting person is the trustee of the Atwood-Edminster Trust and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust.
• The stock option is fully vested.

Negatives

• The initial Form 4 inadvertently omitted the stock options held by the Reporting Person.

Risks

• The earnout shares are subject to forfeiture if certain vesting conditions are not satisfied prior to February 14, 2028.

Future Outlook

The earnout shares are subject to vesting conditions related to the company's stock performance and regulatory milestones, which will determine the final number of shares received.

Industry Context

Form 4 filings are standard practice for company insiders to disclose changes in their beneficial ownership, providing transparency to investors.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the CEO's ownership stake in the company.

Key Dates

Keywords

Form 4, CERO Therapeutics Holdings, Brian Atwood, Stock Options, Beneficial Ownership, Amendment, Atwood-Edminster Trust, Series A Convertible Preferred Stock, Earnout Shares, Business Combination